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What is already known about this topic? 
 There are many different patient and observer-reported measures of eczema 
severity with different levels of evidence for the measurement properties for each 
instrument.  The value of “objective” measures of skin hydration is also unclear. 
 POEM and EASI have been recommended by the Harmonising Outcome Measures 
for Eczema (HOME) initiative as core outcomes for all clinical eczema trials but they 
have not been widely used in community settings/populations with mild eczema. 
 
What does this study add? 
 In children with mostly mild-moderate eczema randomised to one of four emollients 
for 12 weeks, POEM, EASI, SASSAD and TIS all showed a reduction in eczema severity 
but skin hydration (corneometry) did not. 
 There was poor correlation between POEM and observer-reported measures; and 
poor correlation between all these measures and corneometry. 
 The characteristics of POEM and EASI supports their recommendation by HOME as 
core outcomes in trials of eczema treatments. 
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Abstract 
Background: Eczema affects ~20% of children but multiple different outcome measures have 
hampered research into the effectiveness of different treatments. 
Objectives: To compare the change in scores and correlations within and between five 
measures of eczema severity: Patient Orientated Eczema Measure (POEM), Eczema Area 
Severity Index (EASI), Six Area Six Sign Atopic Dermatitis (SASSAD), Three Item Severity (TIS), 
and skin hydration (corneometry). 
 
Methods: Data from a feasibility trial that randomised young children with eczema to one of 
four emollients were used. Participants were followed for three months (84 days). 
Descriptive statistics (by emollient over time) and Spearman’s correlation coefficients 
comparing scores at each time-point and absolute change (between adjacent time-points) 
for each outcome measure were calculated. 
 
Results: 197 children, mean age (SD) of 21.7 (12.8) months, were randomised.  POEM and 
TIS appeared to capture a range of eczema severity at baseline but only POEM had close 
approximation to normal distribution.  Mean POEM, EASI, SASSAD and TIS scores improved 
month-by-month, with POEM showing the greatest sensitivity (effect size 0.42).  
Correlations within POEM, EASI, SASSAD and TIS were moderate-to-good, decreasing over 
time.  Correlations between measures were strongest for EASI, SASSAD and TIS.  By contrast, 
corneometry scores were more variable, correlated less well over time, and were poorly 
correlated with the other measures. 
 
Conclusions: Except for corneometry, all measures appear to change in relation to emollient 
use over time and correlate well with themselves.  POEM demonstrated the greatest range 
of scores at baseline and change in eczema severity over the first 28 days. 
 
Introduction 
Eczema, otherwise known as atopic eczema or dermatitis, is a common and troublesome 
condition, with the greatest burden of disease occurring in pre-school age children.1  
Despite this, evidence to support the use of fundamental treatments such as emollients and 
topical corticosteroids (TCS) is lacking.2 
To be able to compare the effectiveness of different treatments, and inform clinical decision 
making, valid and reliable measures of the outcomes of interest are needed.  However, 
different trials have employed a plethora of different measures, with more than 20 different 
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instruments to measure disease severity,3 14 to measure quality of life,3 and 18 to capture 
patient symptoms.4  Because these instruments assess different aspects of eczema in 
different ways, the results cannot be compared in meta-analyses.  Consequently, evidence-
based clinical decision-making has been hampered. 
To address this, the Harmonising Outcome Measures for Eczema (HOME) group was 
established in 2010 to establish a core outcome set,5 defined as an agreed standardised set 
of outcomes that should be measured and reported, as a minimum, in all clinical eczema 
trials.6  So far it has recommended the Patient Orientated Eczema Measure (POEM)7 and the 
Eczema Area Severity Index (EASI)8 for the patient-reported symptoms and observer-
reported measures of eczema severity, respectively.  However, to date there has been 
limited research comparing the performance of these and other commonly used measures 
(e.g. Six Area, Six Sign Atopic Dermatitis Severity Score – SASSAD,9 Three Item Severity score 
– TIS10) and how they quantify change in eczema severity over time (one measure of 
validity).  In addition, it is common for manufacturers of emollients to evaluate their 
effectiveness in terms of changes in skin hydration, but how this relates to measures of 
eczema symptoms or signs is unclear. 
We have used data from a feasibility trial comparing four commonly used emollients in 
children to compare change in scores over time and correlations within and between 
patient-reported (POEM), observer (EASI, SASSAD, TISS) and skin hydration (corneometry) 
measures of eczema severity. 
 
Methods 
Design, participants and interventions 
Full details of the trial’s methods have been published.11  In brief, COMET was a feasibility 
study of a pragmatic, RCT to compare the clinical and cost-effectiveness of leave-on 
emollients in the treatment of childhood eczema. 
Participants were recruited via general practice (GP) surgeries between July 2014 and April 
2015.  To be eligible, children had to have a clinical diagnosis of eczema, be aged one month 
to under five years and not known to be sensitive or allergic to any of the study emollients 
or their constituents. 
Participants were randomly allocated by a web-based system (1:1:1:1 ratio) to one of four 
emollients (Aveeno® lotionl, Diprobase® cream, Doublebase® gel, or Hydromol® ointment) 
to use as their primary leave-on emollient with the directions to “Use twice daily and when 
required”.  All other care (appointments, prescriptions, referrals) was as per usual.  
Observers undertaking the baseline and follow-up visits (but not clinicians or parents) were 
masked to allocation.  
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Outcomes 
Participants were followed for three months (84 days) by means of daily parent-completed 
diaries and observer visits (usually in the children’s home) every 28 days.  Day 1 was 
recorded as the date of the baseline visit. 
Patient Orientated Eczema Measure (POEM) is a validated, seven item patient-reported 
outcome that asks about the frequency of seven symptoms (itch, sleep disturbance, 
dryness, flaking, weeping or oozing, bleeding and cracking) in the previous week.7 It was 
collected at baseline and thereafter weekly by means of a parent-completed diary, and 
scores range from 0 to 28 (no to severe eczema).  In addition, every 28 days, parents were 
asked to make a global assessment of how their child’s eczema compared with one month 
ago (the Parent Global Assessment, PGA).  Response categories (and scores) were: “Much 
better” (score of 2), “Better” (score of 1), “No difference” (score of 0), “Worse” (score of -1) 
or “Much worse” (score of -2). 
Eczema Area Severity Index (EASI); Six Area, Six Sign Atopic Dermatitis (SASSAD), Three Item 
Severity (TIS) and corneometry (antecubital fossa and forearm, three measurements in each 
area) were collected by a masked observer at the baseline and follow-up visits.  EASI, 
SASSAD and TIS are all scales for grading the physical signs of eczema.  EASI scores (range 0 
to 72) are calculated according to the presence of four features of eczema at four regions of 
the body.12  SASSAD assesses the severity of six signs (erythema, exudation, excoriation, 
dryness, cracking and lichenification) in each of six areas (head and neck, trunk, hands, 
arms, legs and feet).9  The TIS score is based on the evaluation of erythema, 
oedema/papulation and excoriation at a single representative site (range 0 to 9).10  
Children with eczema are known to be born with a defective skin barrier associated with 
higher transepidermal water loss (TEWL).  The application of emollients seeks replace 
moisture in the skin and/or reduce further water loss.  Skin hydration was assessed using a 
corneometer (Corneometer® CM825, Courage & Khazaka electronic GmbH, Cologne, 
Germany), which is a simple and convenient device that measures skin electrical capacitance 
in the outermost layers of the epidermis.  The corneometer was chosen over the 
measurement of TEWL primarily because of the portability and robustness of the 
instrument.  While standardised procedures written in accordance with guidelines on 
biophysical skin measurements were followed,13 measurements were taken in participant’s 
homes under uncontrolled conditions.  Skin hydration (reported in this paper in arbitrary 
units from 0 (wet) to 100 (dry), i.e. a lower score is a more positive outcome) was analysed 
in a multivariate linear regression model adjusted for variations in room temperature and 
humidity.13 
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Sample size 
The main aim of the original trial was to determine the feasibility of a definitive trial to 
compare the clinical effectiveness of four different types of emollients, not the 
responsiveness, etc of the outcomes per se.  Therefore a formal sample size calculation was 
not required.  The target sample size of 160 randomised participants was pragmatic.11 
 
Hypotheses about changes in scores and strengths of correlations 
We hypothesised that the three different types of measure (parent-reported, observer-
reported and corneometry) would all show improvement in eczema severity/hydration in 
relation to emollient use over time (from baseline to 3 months) and in relation to the PGA.  
We also expected to see: a stronger correlation between PGA and POEM, than that between 
PGA and the other measures; stronger correlations between observer-measures (EASI, 
SASSAD and TIS) than between patient-reported (POEM), observer-reported, and skin 
hydration measures; and for those correlations to all be in the same direction (less severe 
eczema/better skin hydration). 
 
Analysis 
Simple descriptive statistics (mean and standard deviation (SD), median and interquartile 
range, (IQR), minimum and maximum values) were calculated for all outcome measures, 
together with the proportion of participants with minimum and maximum scores at baseline 
and the first follow-up month. 
Change scores were calculated by subtracting the current month’s score from that of the 
previous month.  Therefore, a positive change is an improvement over time.  As the POEM 
was assessed weekly, the first month’s score was equated to that of the last week, i.e. 
month 1 = week 4, and so on. Responsiveness is the ability of an outcome measure to detect 
change over time,14 which is reported as an effect size (mean change in score at day 
28/baseline SD). 
Spearman’s correlation coefficients were calculated, comparing raw scores of each outcome 
measure over time and absolute change scores (between adjacent time points) in each 
outcome.15  Bootstrap 95% confidence intervals (CI) were calculated for the Spearman’s 
correlation coefficients of absolute change scores as there were multiple observations of 
each outcome per participant due to multiple time-points where outcome measures were 
collected.  Regarding interpretation of the strength of correlations, we adopted the 
accepted “rules of thumb” of >=0.70 as strong, 0.50-0.69 as moderate and <=0.50 as weak.16 
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Ethics 
COMET was approved by the Central Bristol Research Ethics Committee (REC reference: 
13/SW/0297); Clinical Trial Authorisation was granted by the Medicines and Healthcare 
products Regulatory Agency (MHRA reference: 03299/0017/001-003), and research 
governance approvals were obtained across all areas prior to the start of recruitment.  The 
trial was prospectively registered with ISRCTN (21828118) and EudraCT (2013-003001-26).  
No additional ethical approval was required for the present study. 
 
Results 
Participant recruitment, characteristics and follow-up 
Participant recruitment and follow-up by treatment allocation are shown in Figure 1.  
Participant’s detailed characteristics are presented in Table S1.  In summary, 197 children 
were randomised, with a mean age (SD) of 21.7 months (12.8), 85 (43%) female and 155 
(85%) white.  For various parent-related reasons, the follow-up appointment to acquire the 
observer-collected measures did not always take place when due (Figure S1).  Overall, 75.7% 
of visits took place +/- 5 days and 97.3% took place +/- 10 days of scheduled follow-up 
dates. 
 
Distributions of measures at baseline  
Baseline eczema severity and corneometry are presented in Table 1, and Figure 2 shows the 
baseline score distributions.  POEM displays a close approximation to a normal distribution, 
with scores across its whole range: 5 (2.6%) participants scored the minimum (0) and 1 
(0.5%) scored the maximum (28).  While some participants had minimum and maximum 
scores on TIS, none had the maximum scores on SASSAD and EASI, and all three measures 
were more negatively skewed. 
 
Summary measures for corneometry at the two sites were similar at baseline and follow-up 
(Table 1), and were approximately normally distributed.  Active eczema, which may affect 
the readings, was reported more commonly at the antecubital site at baseline (32.6%, 
58/178 vs 19.2%, 34/177) and at the first follow-up visit (23.7%, 36/152 vs 11.8%, 18/152). 
Mean measure scores and changes over time 
Figure 3 shows the mean scores and 95% CIs for POEM, EASI, SASSAD, TIS and corneometry 
for each emollient over the three follow-up time points.  As expected, scores decreased 
over time for POEM, EASI, SASSAD and TIS, reflecting an improvement in participants’ 
eczema.  In contrast, corneometry readings over time were much more variable, with 
apparent worsening (higher scores) for some emollients.  
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The greatest improvement in eczema severity (for all measures except corneometry) was 
observed over the first 4 weeks (Table S2).  Score averages, ranges, and changes in scores 
over this period are summarised in Table 1.  The largest effect size estimate over this time 
was observed with POEM.   
 
Correlations within measures 
When compared across the different time points, POEM, EASI, SASSAD, TIS all appear to 
have moderate-to-good (0.41 to 0.80) correlations with themselves (Table 2).17  That is, the 
scores at baseline, visit one, and visit two correlated well with subsequent scores.  The 
correlations become less strong the greater the time interval between measurements, i.e. 
correlations between baseline-visit one, visit one-visit two and visit two-visit three were all 
higher than baseline-visit two, baseline-visit three.  Corneometry generally correlated less 
well over time. 
 
Correlations between measures 
Correlations of change scores over time between measures, and in relation to PGA, at all 
time points are presented in Table 3.  As hypothesised, the strongest correlations were seen 
between the observer-reported measures: EASI and SASSAD (0.70, 95% CI 0.65 to 0.76), 
SASSAD and TIS (0.59, 95% CI 0.52 to 0.66) and EASI and TIS (0.51, 95% CI 0.43 to 0.59).  In 
decreasing order of strength of correlation, POEM, SASSAD, EASI and TIS were correlated 
with PGA.  The weaker correlations between POEM and EASI, SASSAD and TIS, and the 
moderate correlation between POEM and PGA, were also expected.  Corneometry was very 
poorly correlated with all other measures.   
 
Discussion 
Summary 
We believe that this is the first paper of its type to compare patient, observer and 
corneometry measures of eczema severity/skin hydration using a sizeable dataset collected 
from a community-based population.  At baseline, the POEM and TIS measures captured a 
range of eczema severity (participants with minimum and maximum scores) but only POEM 
was shown to have a close approximation to the normal distribution.  Mean POEM, EASI, 
SASSAD and TISS improved month-by-month, with POEM showing the greatest sensitivity to 
change (effect size 0.42).  Correlations within POEM, EASI, SASSAD and TIS were moderate-
to-good, decreasing over time.  Perhaps unsurprisingly, the observer-administered 
measures (EASI, SASSAD and TIS) correlated mostly strongly.  On the other hand, 
corneometry scores were more variable, correlated less well over time, and were poorly 
correlated with the other measures. 
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Strengths and weaknesses 
Unlike previous comparable studies (see below), data were obtained from children recruited 
from the community who were taking part in a pragmatic trial.  The parameters describing 
the performance of the different measures are therefore representative of most children 
with eczema, who have mild or moderate disease.  In addition, comparing measure 
responsiveness over the period of greatest change (between baseline and visit one) gave a 
more conservative estimate of each measure’s performance.  The same observer undertook 
the EASI, SASSAD and TIS assessments together at each visit, but monthly follow up of each 
participant was not necessarily conducted by the same observer.  This may have increased 
measure variability between visits, but the within measure comparisons between visits 
(Table 2) and between measures across visits (Table 3) should not be artificially inflated.  We 
did not did not undertake any inter-rater reliability work so we are unable to comment in 
this. 
Different methods are available to measure the water content of the outer layers of 
epidermis and there are few studies comparing these approaches with the patient-reported 
or clinical assessments in our study.  Corneometry readings were collected in participants’ 
homes with variable temperature and humidity, which we measured and adjusted for in our 
analyses.13  However, the observed variability in readings may reflect other factors, such as 
time since bathing or application of emollient.  While it is possible that corneometry 
measurements may reflect differences in the properties of different emollients, the original 
trial (and therefore this study) was not designed to compare outcome measures between 
the treatment groups over time. The apparent worsening in skin hydration may be the result 
of parents remembering to avoid emollient application close to the time of the observer 
visit and corneometry measurement. 
Most participants in COMET were white and the measures may perform differently in 
children with darker skin.  The numbers analysed at each subsequent time point decrease 
either because of missing data or due to participant withdrawal from the study.  Because 
POEM was collected using a parent-completed diary, while the other measures were 
acquired at the “monthly” follow-up visits, the parent and observer-reported measures 
were not done on the same day.  However, over three-quarters of visits took place within 5 
days, and 97% within 10 days, of the scheduled dates.  Finally, there was only a patient 
global assessment against which to compare these measures, not an investigator global 
assessment (IGA).  Therefore, while in a separate paper,18 we have estimated the minimal 
clinically important difference (MCID) for POEM, we have been unable to undertake 
comparable analysis for EASI, SASSAD or TIS.  Typically, 0.5 of baseline SD is used to estimate 
MCID, yielding: EASI 1.9, SASSAD 4.2 and TIS 0.9. 
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Literature 
The measurement properties of the POEM, EASI, SASSAD and TIS have recently been 
reviewed by Schmitt et al19 and Gerbens et al.4  POEM has mainly been evaluated in 
secondary or tertiary care populations and the methodological quality of the studies have 
mostly been judged to be fair or poor.4  The evidence is strongest for its internal validity, 
content validity, responsiveness and interpretability. Our findings provide new evidence for 
its responsiveness to change,4 in children with mainly mild/moderate eczema.  Other studies 
will help address concerns about the absence of redness and pain/soreness as symptoms, 
the focus of POEM on frequency rather intensity of symptoms, and its lack of structural and 
cross-cultural validation.4   
As for the objective measures examined in this paper, few studies have been undertaken in 
primary care settings (EASI 1/9, SASSAD 1/5, TIS 3/7).19  Evidence of content validity, 
internal consistency, intra-observer reliability and sensitivity to change is greatest for EASI, 
while evidence of floor/ceiling effects is better for SASSAD and TIS.19  We present novel data 
on floor/ceiling effects for EASI, and sensitivity to change for SASSAD and TIS.  Schmitt et al19 
have previously noted that the content and measurement properties of patient-reported 
(SA-EASI and PO-SCORAD) and objective measures (EASI and SCORAD respectively) differ 
substantially.  The lower correlation we report between POEM and EASI, SASSAD and TIS 
provides further evidence that they should not be used interchangeably. 
Many different patient and clinician-reported measures have been variously compared in 
other studies, but few published papers have compared between the eczema severity 
measures presented here.  EASI was found to be correlated with SASSAD (r = 0.86) in one 
study of 50 Korean children,20 while SASSAD, EASI and TIS21 and POEM and EASI22 and have 
recently been compared in two small studies (12 and 25 participants, respectively) of 
patients (9 and 13 children, respectively) with moderate or worse eczema. Good inter-rater 
reliability was reported for EASI and SASSAD but not for TIS; however, excellent intra-rater 
reliability for EASI and TIS and good intra-rater reliability for SASSAD was found.  No 
correlation was seen between POEM and SASSAD, EASI or TIS; no other between-measure 
correlations were reported. 
While we found poor correlation between skin hydration measured using corneometry and 
all other measures, Holm et al23 have reported a moderate correlation (r = -0.53) between 
EASI and skin capacitance.  Correlations have also been reported with other objective 
measures of eczema severity (SCORAD23-25 ADSI23).  However, studies were smaller, the ages 
and severity of participants in these differ to the present one and some measurements were 
taken from different sites after acclimatising in a room with fixed temperature and 
humidity.  Even in controlled settings, corneometry is less precise compared to other 
methods26 and, as discussed above, other factors may have contributed to the variability 
that we observed. 
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Research and practice 
The findings of our study support the adoption by HOME of POEM and EASI as the core 
patient and observer (including clinician)-reported outcome instruments, respectively, for 
trials of eczema treatments.  We have provided further evidence that patient-reported and 
objective measures of eczema severity are not inter-changeable.  Therefore, whether being 
used in the clinic, or as part of a research study, the choice of measure should reflect which 
perspective is judged to be of greatest importance (or possibly both types of assessment 
should be used).  Correlations within these groups (POEM with PGA; EASI, SASSAD and TIS 
with each other) are reasonable though, meaning other properties of the measures need to 
be considered when deciding which one to use.  Our findings of high variability in the 
corneometry readings over time, and the low correlations with other measures, question 
whether this method should be used to determine the effectiveness of emollients or other 
topical treatments for eczema, at least in community/pragmatic trial settings. 
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Table 1: Total scores and change of scores on individual measures 
 
Measure 
Scale 
range 
Baseline (day 1) Visit 1 (day 28) Change score 
Mea
n  
(SD) 
Median 
(25th, 
75th 
percentil
e) 
Range 
Mea
n 
(SD) 
Median 
(25th, 75th 
percentile
) 
Range Mean 
(SD) 
% 
effect 
size† 
Min Max Min Max 
Scor
e 
% n 
Scor
e 
% n 
Scor
e 
% n 
Scor
e 
% n 
POEM 
0 – 28 
8.8 
(5.9) 
8 
(4, 12) 
0 2.6 5 28 0.5 1 
5.7 
(5.4) 
4 
(2, 8) 
0 
11.
1 
1
7 
27 0.7 1 
2.5 
(4.9) 
42.4 
EASI 
0 – 72 
2.9 
(3.8) 
1.6 
(0.6, 3.8) 
0 6.5 
1
2 
26 0.5 1 
2.3 
(3.1) 
1 
(0.4, 3.2) 
0 
10.
9 
1
7 
23.2 0.6 1 
0.5 
(2.2) 
13.2 
SASSAD 0 – 
108 
8.8 
(8.4) 
6 
(3, 11) 
0 3.8 7 46 0.5 1 
7.5 
(7.4) 
5 
(3, 10) 
0 5.0 8 37 1.3 2 
0.91 
(4.7) 
10.8 
TIS 
0 – 9 
2.0 
(1.7) 
2 
(1, 3) 
0 
12.
4 
2
3 
9 0.5 1 
1.9 
(1.7) 
1 
(1, 2) 
0 
17.
0 
2
7 
8 0.6 1 
0.1 
(1.5) 
5.9 
Corneomet
ry 
                  
 
Forearm 
0 – 
100 
68.0 
(11.
2) 
68.4 
(60.3, 
76.1) 
33.6 0.6 1 99.5 0.6 1 
64.8 
(12.
6) 
67.2 
(60.4, 
71.5) 
19.6 0.7 1 89.7 0.7 1 
3.1 
(11.3) 
27.7 
Antecubital 
fossa 
0 – 
100 
62.2 
(13.
9) 
63 
(54.3, 
72.7) 
13.4 0.6 1 94.6 0.6 1 
61.1 
(13.
0) 
60.7 
(54.7, 
68.8) 
26.7 0.7 1 96.6 0.7 1 
1.4 
(14.5) 
10.1 
† Mean change score/baseline SD 
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Table 2: Comparison within measures: POEM, EASI, SASSAD, TIS and corneometry 
Spearman’s correlation coefficient between outcome measurements at four different time-
points 
 Baseline Visit 1 Visit 2 Visit 3 
POEM     
Baseline 1    
Month 1 0.4967    1   
Month 2 0.4121 0.6831    1  
Month 3 0.4062    0.5739    0.7080 1 
EASI     
Baseline 1    
Month 1 0.6629    1   
Month 2 0.5456   0.6034   1  
Month 3 0.4986    0.4981    0.5862    1 
SASSAD     
Baseline 1    
Month 1 0.7071 1   
Month 2 0.5945 0.6515 1  
Month 3 0.5391 0.5853 0.6447 1 
TIS     
Baseline 1    
Month 1 0.5692 1   
Month 2 0.4142 0.4799 1  
Month 3 0.3924 0.4230 0.6167 1 
Corneometry antecubital fossa     
Baseline 1    
Month 1 0.2699 1   
Month 2 0.1996 0.3732 1  
Month 3 0.3573 0.4485 0.3224 1 
Corneometry forearm     
Baseline 1    
Month 1 0.5287 1   
Month 2 0.4633 0.6140 1  
Month 3 0.2579 0.3934 0.5151 1 
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Table 3: Comparison of change between POEM, EASI, SASSAD, TIS and corneometry (antecubital and forearm) over all time points 
 POEM EASI SASSAD TIS Corneometry 
antecubital fossa 
Corneometry 
forearm 
PGA 
POEM 1       
EASI 0.20 (0.09, 0.30) 
0.000 
1      
SASSAD 0.26 (0.17, 0.36) 
0.000 
0.70 (0.65, 0.76) 
0.000 
1     
TIS 0.12 (0.02, 0.22) 
0.020 
0.51 (0.43, 0.59) 
0.000 
0.59 (0.52, 0.66) 
0.000 
1    
Corneometry 
antecubital 
fossa 
0.02 (-0.09, 0.13) 
0.714 
0.16 (0.05, 0.27) 
0.003 
0.13 (0.02, 0.23) 
0.017 
-0.03 (-0.14, 0.08) 
0.589 
1   
Corneometry 
forearm 
0.09 (-0.02, 0.20) 
0.112 
0.09 (-0.02, 0.20) 
0.091 
0.11 (0.00, 0.23) 
0.044 
0.10 (-0.01, 0.20) 
0.070 
0.35 (0.25, 0.45) 
0.000 
1  
PGA 0.40 (0.31, 0.49) 
0.000 
0.33 (0.24, 0.41) 
0.000 
0.37 (0.29, 0.46) 
0.000 
0.24 (0.15, 0.33) 
0.000 
0.04 (-0.07, 0.15) 
0.487 
0.03 (-0.08, 0.14) 
0.614 
1 
Spearman’s correlation coefficient comparing absolute change (between adjacent time points) in each outcome with bootstrapped 95% 
confidence intervals and p-values. 
# Corneometry outcomes are the results from the defined model (reported here as lower score representing a positive outcome of more 
hydrated (wet) skin) 
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Figure 1: CONSORT – recruitment and follow-up by treatment allocation 
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Figure 2: Distribution of POEM, EASI, SASSAD, TIS and corneometry at baseline 
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Figure 3: Mean POEM, EASI. SASSAD, TIS and corneometry (95% CI) over time by 
emollient 
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